近日，福建海西新药创制股份有限公司向港交所更新招股书，再度发起港股上市冲击。这家名称凸显“新药”属性的药企，核心业绩却高度依赖仿制药业务——2022至2024年，仿制药收入占比连续三年超90%，其中集采中标品种贡献近六成营收，成为驱动业绩增长的核心引擎。 招股书数据显示，受益于国家及省级带量采购政策，海西新药近三年业绩增速显著，年复合增长率达48.4%，净利润同步翻倍。但繁荣背后隐忧凸显：主力...
Source Link近日，福建海西新药创制股份有限公司向港交所更新招股书，再度发起港股上市冲击。这家名称凸显“新药”属性的药企，核心业绩却高度依赖仿制药业务——2022至2024年，仿制药收入占比连续三年超90%，其中集采中标品种贡献近六成营收，成为驱动业绩增长的核心引擎。 招股书数据显示，受益于国家及省级带量采购政策，海西新药近三年业绩增速显著，年复合增长率达48.4%，净利润同步翻倍。但繁荣背后隐忧凸显：主力...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.